Followers | 40 |
Posts | 1920 |
Boards Moderated | 0 |
Alias Born | 11/08/2011 |
Tuesday, February 25, 2020 3:51:31 PM
1. Cancellation of acquiring J3 Holdings
2. Cancellation of deal with Orgaceutical Co.
3. Apparent fib on repayment of short-term debt by $373,940 (latest financials (Note 8) show only $41,217 was paid in all of 2019)
4. Failure of Artillery Labs deal
5. Zero revenues for 2019 despite acquisition of Vivis and complete lack of marketing their product
6. Increasing outstanding shares in 2019 from 32 million to over 547 million+
7. Re-incorporating to Wyoming and eliminating the cap (unlimited) authorization to issue shares
8. Growing the accumulated deficit to $9.3 million+
9. Draining what little cash they started with in 2019 to near zero
10. Claiming acquisition of Vivis included inventory - but financials show zero dollar value of same
11. Failure to pay the previous CEO his salary of $80,200
12. Negative working capital of nearly $1 million for this one man show
13. Thru Oct. 2019, the Company has raised nearly $7.9 million in cash as additional paid-in-capital. Have you ever wondered where that money went and what it was spent on?: https://www.instagram.com/sydjim/?hl=en
14. The company promised by the end of January to have closed the "acquisition" of an undisclosed property for an undisclosed sum of money, with a fresh influx of unknown funding that is now being diverted for some sort of undisclosed technology tie-in, for an undisclosed purpose, presumably to warehouse inventory they do not have, in a State (Florida) that is not geographically close to its Operations (Texas), with employees to run the operation they do not have with a non-existent advertising budget to pursue their alleged retail division (Vivis) in order to pay back the CEO the hefty sum to acquire the operation (with ongoing royalty checks) that no one has ever heard of so they can claim to have another "successful" year of not actually doing anything (again) <whew>
NTRR = N-TURD
Recent NTRR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 09:15:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/14/2023 08:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:21:12 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM